Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB11 | O95342 | 2/20 | 0.53 |
| ▸ | CCR2 | P41597 | 12/20 | 0.52 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.42 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21465576 | 0.88 | ABCB11 (0.56) | ABCB11CCR2MAPTMEN1CYP3A4 | |
| SCHEMBL21465479 | 0.87 | ABCB11 (0.67) | ABCB11CCR2PLA2G2AMAPTMEN1 | |
| SCHEMBL6302484 | 0.86 | CCR2 (0.61) | ABCB11CCR2MAPTMEN1CYP3A4 | |
| SCHEMBL21465543 | 0.81 | CCR2 (0.57) | ABCB11CCR2MAPTMEN1CYP3A4 | |
| SCHEMBL21465504 | 0.80 | ABCB11 (0.50) | ABCB11CCR2PLA2G2AMAPTMEN1 | |
| SCHEMBL21465506 | 0.80 | PTGS2 (0.47) | MAPTMEN1CYP3A4ALOX15TSHR | |
| SCHEMBL21465488 | 0.79 | MAPT (0.50) | ABCB11CCR2PLA2G2AMAPTMEN1 | |
| SCHEMBL7077464 | 0.79 | CCR2 (0.53) | ABCB11CCR2TBXA2R | |
| SCHEMBL21465545 | 0.79 | ABCB11 (0.51) | ABCB11CCR2PLA2G2AMAPTMEN1 | |
| SCHEMBL23759961 | 0.78 | ABCB11 (0.55) | ABCB11CCR2PLA2G2AMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6953809-B2 | Monocyte chemoattractant protein-1 inhibitor compounds | ZENECA LIMITED (GB) | 2005-10-11 | — | — | US | disclosed |
| US-20030119830-A1 | Monocyte chemoattractant protein-1 inhibitor compounds | ZENECA LIMITED | 2003-06-26 | — | — | US | disclosed |
| US-6441004-B1 | INDOLE DERIVATIVES AS ANTIINFLAMMATORY AGENTS | ZENECA LIMITED (GB) | 2002-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030119830-A1 | Monocyte chemoattractant protein-1 inhibitor compounds | CCL2, CCL11, CCR1 | ABCB11 506/4885CCR2 4/4885PLA2G2A 3294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.